Prothena
Update in progressPRTA (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Prothena Corporation plc is a late‑stage biotechnology company focused on discovering and developing therapies for diseases caused by protein dysregulation. Its pipeline includes prasinezumab (Phase 3 for Parkinson’s and synucleinopathies), coramitug (Phase 3 for transthyretin amyloidosis), BMS‑986446 (Phase 2 for Alzheimer’s), PRX019 (Phase 1 for neurodegenerative diseases), and PRX123 (preclinical for Alzheimer’s). It also works on TDP‑43 CYTOPE, PRX012 (Phase 1), and PRX012‑TfR (preclinical). It collaborates with Roche and Bristol Myers Squibb. Based in Dublin, Ireland.
Company score
- Sentiment
- -0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.26
- Governance
- -0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!